Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Hormone Molecular Biology and Clinical Investigation|May 12, 2015
The antihormonal preventive therapy of breast cancer and prostate cancerHans-Jörg Senn, Rudolf Morant, Florian OttoEuropean Urology|January 1, 2003
Prostate specific antigen doubling time as auxiliary end point in hormone refractory prostatic carcinomaHans-Peter Schmid, Rudolf Morant, Jürg Bernhard, et al.Urologia Internationalis|June 13, 2015
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumKurt Miller, Rudolf Morant, Arnulf Stenzl, et al.BMC Cancer|March 7, 2021
Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effectsChristian Herrmann, Rudolf Morant, Esther Walser, et al.Breast (Edinburgh, Scotland)|July 7, 2005
Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancerGregor Fürstenberger, Eva Senn, Rudolf Morant, et al.Breast Cancer Research : BCR|May 27, 2024
Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survivalDavid Kuklinski, Marcel Blum, Jonas Subelack, et al.Breast Cancer Research and Treatment|February 11, 2025
Risk factors for interval breast cancer: insights from a decade of a mammography screening programJonas Subelack, Rudolf Morant, Marcel Blum, et al.European Radiology|August 4, 2025
Retrospective evaluation of interval breast cancer screening mammograms by radiologists and AIJonas Subelack, Rudolf Morant, Marcel Blum, et al.Pageof 3